病毒来源的免疫刺激性RNA在疫苗接种中诱导I型干扰素依赖性抗体和T细胞应答
研究探讨源自仙台病毒缺陷病毒基因组的268核苷酸寡核苷酸(DDO)作为流感疫苗佐剂的作用。在小鼠灭活甲型流感病毒疫苗中,DDO诱导稳健的IgG2c抗体产生、Th1和CD8+ T细胞应答,并能抵抗异亚型甲型流感病毒攻击;DDO与AddaVax协同使免疫应答向1型免疫偏移,其佐剂效应严重依赖I型干扰素信号。
要点
- DDO作为灭活甲型流感病毒疫苗佐剂可诱导稳健的IgG2c抗体产生。
- DDO诱导Th1和CD8+ T细胞应答,能抵抗异亚型甲型流感病毒攻击。
- DDO与AddaVax协同使免疫应答向1型免疫偏移,佐剂效应依赖I型干扰素信号。
核心结论
- 数据支持I型干扰素在疫苗接种中诱导1型免疫应答的关键作用,并证明DDO是一种1型免疫导向的疫苗佐剂,可单独使用或与其他佐剂协同使用。
研究设计与样本
- 研究为实验性动物研究,使用灭活甲型流感病毒(IAV)疫苗在小鼠中评价DDO的佐剂效应。
主要发现
- DDO在灭活IAV疫苗中诱导稳健的IgG2c抗体产生。
- DDO诱导Th1和CD8+ T细胞应答,能抵抗异亚型IAV攻击。
- DDO与AddaVax协同使免疫应答向1型免疫偏移。
- DDO单独及与AddaVax协同的佐剂效应严重依赖I型干扰素信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuvants potentiate and direct the type of immunity elicited during vaccination. However, there is a shortage of adjuvants that elicit robust type-1 immunity required for the control of intracellular pathogens, including viruses. RNA derived from Sendai virus defective viral genomes (DVGs) stimulates RIG-I-like receptor signaling leading to type-1 immunity during infection. Here, we investigated whether a 268nt DVG-derived oligonucleotide (DDO) functions as a strong type-1 immunity-inducing adjuvant during vaccination against influenza virus. We show that DDO induces robust IgG2c antibody production when used in an inactivated influenza A virus (IAV) vaccine. Additionally, DDO induces Th1 and CD8+ T-cell responses able to protect against heterosubtypic IAV challenge. Interestingly, DDO synergized with AddaVax and skewed the immune response towards type-1 immunity. The adjuvancy of DDO alone and in synergy with AddaVax was heavily dependent on type I interferon signaling. Our data support a critical role for type I interferon in the induction of type-1 immune responses during vaccination and demonstrate that DDO is a type-1 immunity orienting vaccine adjuvant that can be used alone or in synergy with other adjuvants.
引用
- Fisher DG, Coppock GM, López CB, et al. Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination. Vaccine. 2018. PMID: 29861183. doi:10.1016/j.vaccine.2018.05.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。